Trian Fund
Trian Fund is the hedge fund family controlled by 'operational' activist investor Nelson Peltz.
Nelson Peltz in an American billionaire. He is Chairman of Triarc Companies (NYSE: TRY), the franchisor of the Arby's restaurant in the US and Canada. Peltz is also CEO and Founding Partner of Trian Fund Management, L.P, a New-York based investment company.
Nelson Peltz in an American billionaire. He is Chairman of Triarc Companies (NYSE: TRY), the franchisor of the Arby's restaurant in the US and Canada. Peltz is also CEO and Founding Partner of Trian Fund Management, L.P, a New-York based investment company.
View Older Stories
-
Wedbush Initiates Solventum (SOLV) to Outperform
-
Form SCHEDULE 13D/A JANUS HENDERSON GROUP Filed by: TRIAN FUND MANAGEMENT, L.P.
-
Form 4 JANUS HENDERSON GROUP For: May 12 Filed by: TRIAN FUND MANAGEMENT, L.P.
-
Form 4 JANUS HENDERSON GROUP For: May 12 Filed by: TRIAN FUND MANAGEMENT, L.P.
-
Argus Upgrades Wendy's (WEN) to Buy
-
Form 144 JANUS HENDERSON GROUP Filed by: TRIAN FUND MANAGEMENT, L.P.
-
Wendy's stock surges on report of potential buyout bid
-
Peltz's Trian seeks funding for Wendy's take-private bid, FT reports
-
Janus Henderson Group plc Reports First Quarter 2026 Results
-
THE WENDY'S COMPANY REPORTS FIRST QUARTER 2026 RESULTS
-
Trianz Launches Concierto Agentic at AWS Summit Singapore - Unifying Enterprise Transformation Across Apps, Data, and Infrastructure
-
Trian urges Solventum board to create value, cites executive pay concerns
-
Trian pushes Solventum for changes after $13 billion value loss
-
Trian Calls on Solventum's Board to Create Value; Publishes Open Letter and Slide Deck
-
Trian Calls on Solventum's Board to Create Value; Publishes Open Letter and Slide Deck
-
Trian Sends Letter To Solventum Board Urging Changes - CNBC
-
Janus Henderson to Report First Quarter 2026 Results
-
Trianz Appoints Sudhakar Vadapalli as Chief Financial Officer to Lead Next Phase of Platform-Led Growth
-
Janus Henderson shareholders approve Trian, General Catalyst buyout
-
Janus Henderson Announces Resounding Shareholder Approval of the Trian and General Catalyst Transaction
-
TRIANA Biomedicines Announces Oral Presentation of TRI-611 and Additional Poster Presentations at the American Association for Cancer Research Annual Meeting 2026
-
BofA Securities Resumes Unilever plc (UL) at Buy
-
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Soleno Therapeutics, Inc. (Nasdaq – SLNO), Affinity Bancshares, Forian, Inc. (Nasdaq – FORA), Janus Henders
-
Janus Henderson Group (JHG) PT Raised to $52 at TD Cowen
-
TRIANA Biomedicines’ TRI-611 Granted U.S. FDA Fast Track Designation for Treatment of ALK Positive Non-small Cell Lung Cancer
-
Form SCHEDULE 13D/A JANUS HENDERSON GROUP Filed by: TRIAN FUND MANAGEMENT, L.P.
-
Form DFAN14A JANUS HENDERSON GROUP Filed by: TRIAN FUND MANAGEMENT, L.P.
-
Trian and General Catalyst amend merger agreement with Janus Henderson to $52 per share
-
Trian and General Catalyst Amend Merger Agreement with Janus Henderson at Increased Price of $52.00 Per Share in Cash
-
Victory Capital abandons Janus Henderson bid, clearing path for Trian-led deal
-
Trian and General Catalyst increase Janus Henderson offer to $52 per share
-
Trian and General Catalyst Agree to Increase Merger Consideration to $52.00 Per Share in Cash for Janus Henderson Group plc and Have Made the Only Actionable Proposal
-
Victory Capital fires back at Peltz's Trian as Janus bidding war drags on
-
Victory Capital defends Janus Henderson acquisition proposal
-
Victory Capital Sets the Record Straight on Actionability of Its Clearly Superior Proposal to Acquire Janus Henderson
-
Form DFAN14A JANUS HENDERSON GROUP Filed by: TRIAN FUND MANAGEMENT, L.P.
-
Trian opposes Victory's sweetened rival bid for Janus Henderson
-
Form DFAN14A JANUS HENDERSON GROUP Filed by: TRIAN FUND MANAGEMENT, L.P.
-
Trian opposes Victory Capital bid for Janus Henderson
-
Trian Releases Investor Presentation Explaining Its Strong Opposition to Victory Capital’s Latest Proposal For Janus Henderson
-
TRIANA Biomedicines Announces First Patient Dosed in a Phase 1/2 Trial Evaluating TRI-611 for the Treatment of ALK Positive Non-small Cell Lung Cancer
-
CIM Group Announces Global Client Group Leadership Appointments
-
Janus Henderson clients, staff push to reject Victory Capital's takeover bid, WSJ reports
-
Disney's new CEO Josh D'Amaro steps up for a wild ride
-
Janus Henderson receives revised proposal from Victory Capital
-
Janus Henderson Special Committee Confirms Receipt of Revised Unsolicited, Non-Binding Proposal from Victory Capital
-
Victory Capital sweetens $8.6 billion Janus Henderson bid with more cash
-
Victory Capital raises offer for Janus Henderson to $56.84 per share
-
Victory Capital Submits Improved, Actionable and Clearly Superior Proposal to Acquire Janus Henderson
-
Form DFAN14A JANUS HENDERSON GROUP Filed by: TRIAN FUND MANAGEMENT, L.P.

